Lunai Bioworks Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount
Lunai Bioworks Inc. (LNAI) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount of $122.83 thousand for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-17.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2021-05-17
- Lunai Bioworks Inc. effective income tax rate reconciliation, nondeductible expense, research and development, amount for the quarter ending 2021-03-31 was $122.83K.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 3 month |
|---|---|
| 2021-03-31 | $122.83K 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |